A selective inhibitor targeting ACC1 that shows anti-NAFLD/NASH effects in pre-clinical models is reported in a recent study (115), which is expected to strengthen the efficacy. This evidence concerns the gene ACACA and metabolic dysfunction-associated steatotic liver disease.